Back to discover
Drug

Ertumaxomab

In clinical development
ClassReceptor protein-tyrosine kinase erbB-2 cross-linking agentEmerging researchEarly-to-mid development

Also known as Anti-cd3 x anti-her-2-neu bispecific monoclonal antibody.

RxNorm2686250ChEMBLCHEMBL2108029UNIIL5L45YGP1O
1
Research papers
2
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/Neu Expressing (1+/SISH Positive, 2+ and 3+) Solid Tumors Progressing After Standard Therapy

Clinical trial2016-05-01Terminated · ClinicalTrials.gov

Phase II Study Of The Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/Neu Overexpressing (3+ Or 2+/FISH+) Metastatic Breast Cancer Progressing After Trastuzumab Treatment

Clinical trial2009-12-01Terminated · ClinicalTrials.gov

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

Research2009-04-03The oncologist

Phase II Study for Repeated Dosing of the Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab in Patients With HER-2/Neu 1+ or 2+/FISH Negative Expressing Advanced or Metastatic Breast Cancer (Stage IIIb/IV) Progressing After Endocrine Treatment

Clinical trial2009-02-01Terminated · ClinicalTrials.gov

Phase II Study of the Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab for Hormone Therapy Refractory Patients With Her-2/Neu 1+ or 2+ Expressing Advanced or Metastatic Breast Cancer

Clinical trial2009-02-01Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ertumaxomab
Aliases & brands
Anti-cd3 x anti-her-2-neu bispecific monoclonal antibody
RxNorm CUI
2686250
ChEMBL ID
CHEMBL2108029
UNII
L5L45YGP1O
Primary mechanism
Receptor protein-tyrosine kinase erbB-2 cross-linking agent

Pharmacology & targets

2 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Receptor tyrosine-protein kinase erbB-2
ERBB2 · P04626
CROSS-LINKING AGENTReceptor protein-tyrosine kinase erbB-2 cross-linking agent
T-cell surface glycoprotein CD3 epsilon chain
CD3E · P07766
CROSS-LINKING AGENTT-cell surface glycoprotein CD3 epsilon chain cross-linking agent

Clinical trials

4 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
4
registered trials across all phases
4
Discontinued
PHASE DISTRIBUTIONn = 4
Phase 1 / 21Phase 23

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • The oncologist1
Leading researchers
  • Hortobagyi GN1
  • Pusztai L1
  • Ravdin PM1
  • Ross JS1
  • Slodkowska EA1
  • Symmans WF1
Leading institutions
free-text, unnormalised
  • Department of Pathology and Laboratory Medicine1

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Pertuzumab

Acts on the same molecular target as Ertumaxomab, with an overlapping disease area.

Shared target1 shared disease1 shared paper
Everolimus

Studied across the same disease area as Ertumaxomab in the shared literature.

1 shared disease1 shared paper
Lapatinib

Studied across the same disease area as Ertumaxomab in the shared literature.

1 shared disease1 shared paper
Sirolimus

Studied across the same disease area as Ertumaxomab in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials